chlordecone alcohol: metabolite of kepone in humans; present in bile as its glucuronide conjugate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 13946 |
| CHEBI ID | 17184 |
| SCHEMBL ID | 7515865 |
| MeSH ID | M0094591 |
| Synonym |
|---|
| 1034-41-9 |
| CHEBI:17184 |
| reduced kepone |
| 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-1h-1,3,4-(methanetriyl)cyclobuta[cd]pentalen-2-ol |
| 1,2,3,4,6,7,8,9,10,10-decachloropentacyclo[5.3.0.0(2,6).0(3,9).0(4,8)]decan-5-ol |
| 1,3,4-metheno-1h-cyclobuta(cd)pentalen-2-ol, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro- |
| ai3-24875 |
| ccris 6220 |
| C02817 |
| chlordecone alcohol |
| 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-1,3,4-metheno-1h-cyclobuta(cd)pentalen-2-ol |
| unii-6wgx423wzj |
| 6wgx423wzj , |
| kepone alcohol |
| SCHEMBL7515865 |
| kepol |
| MBEIHNKADVMCJM-UHFFFAOYSA-N |
| 1,3,4-metheno-1h-cyclobuta[cd]pentalen-2-ol, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro- |
| chlordecol |
| j542.309k , |
| DTXSID1024752 |
| Q27102254 |
| 1,2,3,4,6,7,8,9,10,10-decachloropentacyclo[5.3.0.02,6.03,9.04,8]decan-5-ol |
| Class | Description |
|---|---|
| organochlorine compound | An organochlorine compound is a compound containing at least one carbon-chlorine bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||